Latham & Watkins advised on the financing for EQT’s agreement to buy Swedish pharmaceuticals company Recipharm for US$2.1 billion (SEK17.9 billion).

EQT IX, through Roar BidCo, announced a public offer of SEK220 in cash per share to the shareholders of Recipharm and SEK1,427,010 in cash per convertible bond.

Financing for the offer was led by London partners Dominic Newcomb and Jennifer Engelhardt, with counsel Will Lam and associates Melanie Emmen and Medha Vikram. Advice on convertible bonds was provided by London capital markets partner Manoj Tulsiani and associate Amina Tsatiashvili.